Biology's Arnold Caplan weighs in on whether FDA should review stem-cell treatments

MEDIA | September 13, 2016
STORY BY: EDITORIAL STAFF

Boom in unproven cell therapies intensifies regulatory debate Nature: Biology Professor Arnold Caplan weighed in on the debate over whether the Federal Drug Administration should review stem-cell treatments conducted by clinics.